港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

生物醫藥B類股

618.706

+13.1722.18%

漲家數：23

跌家數：8

平家數：3

市盈率：- -

高：627.633

開：605.584

低：600.085

收：605.533

成交量：1.29億

成交額：38.26億

市值：3,831.01億

流通市值：3,410.50億

資料載入中...

中國人的藥，治世界的病

速遞丨10餘款癌症管線正在臨牀推進，和譽醫藥展示創新管線佈局與前沿臨牀進展

新橋生物攜25名全職員工闖關港交所，雲頂新耀、康橋資本參股

28家藥企涉商業賄賂案！多起醫藥虛假宣傳曝光，大聯盟集採中選結果出爐，恆瑞、樂普大爆發

格隆匯港股回購榜 | 10月31日

中國首個，獲批上市！

直擊國談第二日：腫瘤、慢病領域重磅藥開談！

猛犸资本局

騰盛博藥-B(02137)授出60萬份購股權

新股消息 | 禮邦醫藥遞表港交所核心產品AP301已完成中國III期註冊臨牀試驗

智通港股解盤 | 月底魔咒再起恒指跌破關口醫藥目錄談判引發資金湧入

ETF日報：各方面利好消息不斷出現，為行業樂觀情緒再添一把火，關注創新藥板塊

創新藥突然爆發，基金經理火線解讀！多頭猛攻，港股通創新藥ETF（520880）大陽線拔地而起，放量摸高5.25%！

歸創通橋(02190)10月31日耗資約118.74萬港元回購5萬股

邁博藥業-B(02181)：張雁雲已獲指定為首席獨立非執行董事

歌禮制藥-B(01672)10月31日耗資約193.27萬港元回購20萬股

9個月幹了過去3年IPO總和，這個領域何以爆發？

京東健康與醫療器械企業「雙向賦能」共建數字化健康新生態——走進魚躍全球產業化基地

速遞｜歌禮制藥Amylin減肥新藥向FDA申報！進入臨牀開發階段

GLP1减重宝典

聖湘生物(688289.SH)四款產品取得醫療器械註冊證

藥明巨諾與再生元簽署戰略合作補充協議，攜手加速TCR-T療法開發

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":618.7055,"timestamp":1761898110601,"preClose":605.53326,"halted":0,"volume":128593457,"delay":0,"changeRate":0.021753,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":13.172241,"latestTime":"10-31 16:00:00","open":605.58374,"high":627.6333,"low":600.08484,"amount":3826218301,"amplitude":0.045495,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1762133400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1761874200000,1761883200000],[1761886800000,1761897600000]],"pbRate":5.343409,"peRate":-44.036334,"turnoverRate":0.004666,"increases":23,"decrements":9,"flats":1,"marketCap":383100705664,"floatMarketCap":341050329040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":627.6333,"amplitude":0.045495,"preClose":605.53326,"low":600.08484,"pbRate":"5.343409","latestPrice":618.7055,"volume":128593457,"delay":0,"open":605.58374,"prevYearClose":331.1933,"prevWeekClose":617.318,"prevMonthClose":618.706,"prevQuarterClose":752.859,"fiveDayClose":615.593,"twentyDayClose":752.859,"sixtyDayClose":779.344,"secType":"PLATE","market":"HK","turnoverRate":0.004666,"peRate":-44.036334,"marketCap":383100705664,"floatMarketCap":341050329040,"timestamp":1761898110601,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":23,"down":8,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2580441174","title":"中國人的藥，治世界的病","url":"https://stock-news.laohu8.com/highlight/detail?id=2580441174","media":"正和岛","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580441174?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 11:30","pubTimestamp":1761967814,"startTime":"0","endTime":"0","summary":"一次符合国际标准的临床试验，成本动辄数亿美元，却是药企走向世界的必由之路。比如新冠疫情期间，国内主要用的还是布洛芬、对乙酰氨基酚等传统退烧药，真正有效的创新抗病毒药物非常少。中国的创新药，起点确实不高。数据显示，截至今年一季度，全球在研的PD-1药物中，有55%来自中国企业。中国企业基于国内生命科学和化学工程类人才优势，通过短周期分子设计与假设验证的迭代循环，在ADC等领域实现了局部“弯道超车”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101115147a480fed0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101115147a480fed0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1583","LU1969619763.USD","BK1574","09995","06978","BK1161"],"gpt_icon":0},{"id":"2580410734","title":"速遞丨10餘款癌症管線正在臨牀推進，和譽醫藥展示創新管線佈局與前沿臨牀進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2580410734","media":"医药观澜","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580410734?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 09:20","pubTimestamp":1761960030,"startTime":"0","endTime":"0","summary":"10月30日，和誉医药宣布2025研发日在上海成功举办，展示了公司最新创新管线布局与前沿临床进展。ABSK011在1期和2期临床研究中显示出40%至50%的有效率，今年5月份启动的注册性临床覆盖中国国50余家中心。口服小分子PD-L1抑制剂ABSK043在临床研究中展现出类抗体疗效和极佳的口服便利性，同时良好的安全性显示其具备克服多药联合治疗安全性风险的潜力。ABSK043联合其他药物用于晚期NSCLC和胃癌一线治疗的2期临床研究正在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101093525a6d9b6ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101093525a6d9b6ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1515","LU2488822045.USD","BK1574","BK1161","09939"],"gpt_icon":0},{"id":"2580441391","title":"新橋生物攜25名全職員工闖關港交所，雲頂新耀、康橋資本參股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580441391","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580441391?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 09:00","pubTimestamp":1761958800,"startTime":"0","endTime":"0","summary":"瑞财经 刘治颖10月31日，新桥生物向港交所主板提交上市申请书，高盛和中信证券为联席保荐人。新桥生物已于2020年1月22日起在纳斯达克上市交易。若此次顺利完成港交所上市，新桥生物将实现“美股+港股”双重上市格局。截至最后实际可行日期，新桥生物拥有25名全职员工。新桥生物表示，公司主要通过招聘网站、猎头、内部推荐及招聘会等渠道招聘员工，2024年大量员工通过内部推荐加入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110109063394e83810&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110109063394e83810&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2580445494","title":"28家藥企涉商業賄賂案！多起醫藥虛假宣傳曝光，大聯盟集採中選結果出爐，恆瑞、樂普大爆發","url":"https://stock-news.laohu8.com/highlight/detail?id=2580445494","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580445494?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 08:18","pubTimestamp":1761956330,"startTime":"0","endTime":"0","summary":"看点view本周，2025年国谈开启，第十一批国采272家企业的453个产品拟中选，医药反腐再掀风暴，多起医药虚假宣传典型案例曝光。截至目前，国家医保局共开展十一批国家组织药品集采，成功采购490种药品。大联盟集采中选结果出炉10月29日，广东省药品交易中心发布广东联盟常见病慢性病药品接续采购中选结果通知。根据相关规定，责令当事人停止违法行为，并处20万元罚款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101085310a480c74b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101085310a480c74b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","BK1515","BK1574","LU1023057109.AUD","09939","01276","LU0359201612.USD","BK1161","BK1191","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2580449389","title":"格隆匯港股回購榜 | 10月31日","url":"https://stock-news.laohu8.com/highlight/detail?id=2580449389","media":"格隆汇","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580449389?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 08:00","pubTimestamp":1761955200,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为顺丰控股，回购数量497.00万 ，回购金额2.00亿。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/11/01080053948417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02120","IE00B067MR52.USD","09959","09890","01497","LU0140636845.USD","02373","02039","LU0287142896.SGD","BK1160","02190","IE00B031J352.USD","02273","02319","02299","06826","BK1574","LU0048580855.USD","00732","00777","02869","06936","BK1201","08128","BK1103","LU0163747925.USD","LU0251143458.SGD","01583","02416","LU0228367735.SGD","06098","00909","06186","00418","01800","01919","01672","01681","06868","LU0370786039.SGD","LU0029875118.USD","01866","LU0315179316.USD","00103","00300","00386","01586","01373","02598","00947"],"gpt_icon":0},{"id":"2580445490","title":"中國首個，獲批上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2580445490","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580445490?lang=zh_tw&edition=fundamental","pubTime":"2025-11-01 06:22","pubTimestamp":1761949331,"startTime":"0","endTime":"0","summary":"瑞乐唐是国内首个获批的此类产品，填补了国内市场空白。随着该药获批，公司已上市糖尿病新药增至5款，初步构建起覆盖糖尿病全病程的研发与产品矩阵。2025年1月，INS068的上市申请已获国家药监局受理。在持续高强度的研发驱动下，恒瑞创新成果爆发：2025年三季度财报显示，恒瑞已在中国获批上市24款1类创新药、5款2类新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101064731a4809e6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101064731a4809e6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","06978","LU0359202008.SGD","LU1023057109.AUD","BK1161","BK1574","01276","BK1191","LU0359201885.HKD","LU0359201612.USD"],"gpt_icon":0},{"id":"2580490245","title":"直擊國談第二日：腫瘤、慢病領域重磅藥開談！","url":"https://stock-news.laohu8.com/highlight/detail?id=2580490245","media":"猛犸资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580490245?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 22:09","pubTimestamp":1761919791,"startTime":"0","endTime":"0","summary":"10月31日是2025年国家医保谈判的第2日，各大医药企业代表在早上8点前就已排队进入全国人大会议中心。时代周报记者从全国人大会议中心西门现场了解到，第二天谈判主要涉及肿瘤、慢病等重大疾病领域，谈判节奏明显慢于前一天。时代周报记者从场外等候药企代表的交谈中得知，今天谈判药品包括抗肿瘤和慢病类药物，参与谈判多为肿瘤企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031230619a6d928b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031230619a6d928b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575","LU1023057109.AUD","BK1574","LU0359201885.HKD","06978","LU2543165471.USD","BK1161","LU0359202008.SGD","LU0359201612.USD","01276","02616"],"gpt_icon":0},{"id":"2579454467","title":"騰盛博藥-B(02137)授出60萬份購股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454467","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579454467?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 21:29","pubTimestamp":1761917376,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布公告，于2025年10月31日，公司根据2023年购股权计划条款向受让人授出60万份购股权，但须待受让人接纳。于本公告日期，已发行股份总数为7.209亿股(不包括库存股)。根据授出购股权授出的该等购股权获悉数行使后，据此将配发及发行的股份占本公告日期已发行股份总数(不包括库存股)约0.08%及经扩大已发行股份总数约0.08%(不包括库存股)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"腾盛博药-B(02137)授出60万份购股权","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02137","BK1587","BK1161"],"gpt_icon":0},{"id":"2579667467","title":"新股消息 | 禮邦醫藥遞表港交所 核心產品AP301已完成中國III期註冊臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2579667467","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579667467?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 21:08","pubTimestamp":1761916113,"startTime":"0","endTime":"0","summary":"礼邦医药从高磷血症领域切入，如今已拓展至整个肾脏病领域。公司的核心产品AP301是一款潜在BIC的磷酸盐结合剂，用于治疗高磷血症。AP301已完成中国III期注册临床试验，预计于近期提交新药申请，目前正在美国和中国开展全球III期关键多中心临床试验。另外，AP306是一款用于治疗高磷血症的潜在FIC泛磷酸盐转运蛋白抑制剂，已获得中国国家药监局的突破性疗法认定。礼邦医药目前正在探索全球商业及开发合作机会，以最大化AP301及AP306的全球市场价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","09939","BK1161","BK4134","159938","BK1515","BK1574","HEXmain"],"gpt_icon":0},{"id":"2579464507","title":"智通港股解盤 | 月底魔咒再起恒指跌破關口 醫藥目錄談判引發資金湧入","url":"https://stock-news.laohu8.com/highlight/detail?id=2579464507","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579464507?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 20:40","pubTimestamp":1761914421,"startTime":"0","endTime":"0","summary":"恒指收盘跌1.43%，破了26000点关口。周四美股三大指数均出现调整，Meta因其巨额AI支出计划而股价暴跌11%，引发了市场对AI投入产出比的广泛担忧。美国推行关税引发国内的不满，美参议院通过终止特朗普全面关税政策决议，但这些决议接下来还须经众议院表决。今日，2025年国家医保目录现场谈判与商保创新药目录价格协商在北京全国人大会议中心继续推进。今年国谈在延续医保目录常规调整机制的基础上，首次正式引入“商保创新药目录”机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","LU1235295612.USD","02833","BK1535","SG9999001093.SGD","YANG","BK1515","HHImain","09939","HSImain","BK1505","HSI","LU1046422090.SGD","BK4614","159938","01919","MHImain","BK1574","SG9999002950.SGD","BK1186","LU0390135688.USD","02343","SG9999011746.SGD","03877","SG9999001440.SGD","BK1161","LU0390135332.USD","LU0300738605.USD","BK1103","MCHmain","01138","LU0049112450.USD","BK1166","SG9999003461.SGD","LU0390135506.SGD","LU0300738514.USD","513600"],"gpt_icon":0},{"id":"2579462460","title":"ETF日報：各方面利好消息不斷出現，為行業樂觀情緒再添一把火，關注創新藥板塊","url":"https://stock-news.laohu8.com/highlight/detail?id=2579462460","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579462460?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 20:39","pubTimestamp":1761914340,"startTime":"0","endTime":"0","summary":"受隔夜美股科技股表现疲弱等利空因素影响，A股今日小幅低开后震荡下行，前期表现强势的海外映射板块领跌两市。两市涨多跌少，共计3759家上涨，1548家下跌。成交方面，沪深两市成交额约2.35万亿，较昨日缩量超千亿，但仍较上周水平有所放大，市场热度逐渐恢复。　　板块方面，沉寂多日的创新药、软件、传媒等板块领涨。　　产业消息方面，利好消息不断出现，为行业乐观情绪再添一把火。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-31/doc-infvuxsn3202541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4550","BK4585","BK1574","06978","BK1161","159992","BK4588","FDN"],"gpt_icon":0},{"id":"2579469924","title":"創新藥突然爆發，基金經理火線解讀！多頭猛攻，港股通創新藥ETF（520880）大陽線拔地而起，放量摸高5.25%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2579469924","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579469924?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 19:53","pubTimestamp":1761911580,"startTime":"0","endTime":"0","summary":"10月最后一个交易日，沉寂已久的创新药板块突然大爆发，A港同频共振。重仓A股创新药的药ETF场内劲涨2.46%，三生国健20CM涨停。港股创新药尽显高弹性，100%创新药研发标的——港股通创新药ETF放量上探5.25%！业内人士指出，此举有望分流缓解高值创新药的支付压力。　　技术面看港股通创新药ETF，亮点颇多。　　港股通创新药ETF基金经理丰晨成最新表示，创新药行情可能随时再次启动，当下或是中长期维度配置创新药的高胜率区间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-31/doc-infvuxsi8523212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","520880","BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2579463926","title":"歸創通橋(02190)10月31日耗資約118.74萬港元回購5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2579463926","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579463926?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 19:14","pubTimestamp":1761909296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2025年10月31日耗资约118.74万港元回购5万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","02190","BK1574","BK1100","BK1583"],"gpt_icon":0},{"id":"2579633134","title":"邁博藥業-B(02181)：張雁雲已獲指定為首席獨立非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2579633134","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579633134?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 19:07","pubTimestamp":1761908823,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈博药业-B(02181)发布公告，自2025年10月31日起：执行董事钱卫珠博士已获委任为本公司提名委员会成员;执行董事陶静先生已不再担任提名委员会成员;及张雁云博士(本公司独立非执行董事(独董)、本公司薪酬委员会主席及提名委员会成员)已获指定为首席独立非执行董事(首席独董)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02181","BK1574"],"gpt_icon":0},{"id":"2579468627","title":"歌禮制藥-B(01672)10月31日耗資約193.27萬港元回購20萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2579468627","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579468627?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 18:56","pubTimestamp":1761908168,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2025年10月31日耗资约193.27万港元回购20万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01477","BK1191","01672","BK1574","BK1161"],"gpt_icon":0},{"id":"2580249194","title":"9個月幹了過去3年IPO總和，這個領域何以爆發？","url":"https://stock-news.laohu8.com/highlight/detail?id=2580249194","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580249194?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 18:41","pubTimestamp":1761907267,"startTime":"0","endTime":"0","summary":"港股医疗保健行业通过IPO募资金额超过过去3年全年总和。仅9月以来，就有超12家药企向港交所递交IPO申请。截至2025年10月23日，港交所正在处理的上市申请约300家，其中半数为新经济领域企业，涵盖人工智能、生物技术等行业。这是2025年前十个月，中国创新药的大致表现。仅今年上半年，国家药品监督管理局批准创新药达40种，接近2024年全年总量。因为早期投入的企业得到了非常好的回报，这时中国创新药投融资开始爆发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103118432394e75504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103118432394e75504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK1588","LU1969619763.USD","BK1583","LU0307460666.USD","LU0588546209.SGD","06978","BK1574","LU1303224171.USD","LU1719994722.HKD","LU1770034418.SGD","LU2328871848.SGD","LU1251922891.USD","BK1161","BK1500"],"gpt_icon":0},{"id":"2579452089","title":"京東健康與醫療器械企業「雙向賦能」共建數字化健康新生態——走進魚躍全球產業化基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2579452089","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579452089?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 17:55","pubTimestamp":1761904500,"startTime":"0","endTime":"0","summary":"京东健康与鱼跃医疗在江苏丹阳的全球产业化基地展开深度合作，共建数字化健康新生态。京东健康通过其供应链网络，助力鱼跃医疗的智能医疗器械高效触达全国患者与家庭，实现从制造到终端的全链路服务。双方合作不仅是销售渠道的对接，更是基于数字化与供应链能力的深度共建。京东健康依托全国仓储物流体系，提升鱼跃产品流通效率，实现“当日达”“次日达”。同时，京东健康供应链管理系统与鱼跃制造体系高效协同，通过消费大数据动态调整布货计划，精准响应市场需求。此外，京东健康还助力鱼跃从“制造”转向“智造”，基于用户数据洞察推出具有房颤识别功能的电子血压计等创新产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031180724a47fc569&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031180724a47fc569&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1515","SGXZ86797644.SGD","BK1100","BK1591","LU0051755006.USD","BK1142","BK1589","BK1583","86618","06618","BK1571","09997","SGXZ62798434.SGD","BK1574","LU0456827905.SGD","BK1615","BK1247","BK1222"],"gpt_icon":0},{"id":"2580416212","title":"速遞｜歌禮制藥Amylin減肥新藥向FDA申報！進入臨牀開發階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2580416212","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580416212?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 17:53","pubTimestamp":1761904426,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队2025年10月30日，歌礼制药有限公司宣布，已选定一款有望成为同类最佳每月一次皮下注射胰淀素受体激动剂ASC36作为临床开发候选药物。歌礼预计将于2026年第二季度向美国食品药品监督管理局递交ASC36治疗肥胖症的新药临床试验申请。ASC36是利用歌礼基于结构的AI辅助药物发现和超长效药物开发平台技术自主研发的胰淀素受体激动剂多肽。每毫克多肽的减重效果更优，也可能使ASC36在规模化生产中成本更低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031200933a47ffba9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031200933a47ffba9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01477","01672","BK1574","BK1515","BK1191"],"gpt_icon":0},{"id":"2579545244","title":"聖湘生物(688289.SH)四款產品取得醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2579545244","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579545244?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 17:50","pubTimestamp":1761904233,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣湘生物 发布公告，公司的四款产品于近日收到由国家药品监督管理局颁发的《医疗器械注册证》，包括呼吸道合胞病毒核酸检测试剂盒、甲型流感病毒、乙型流感病毒、腺病毒核酸检测试剂盒、甲型流感病毒、乙型流感病毒、肺炎支原体核酸检测试剂盒和人鼻病毒、腺病毒、肺炎支原体核酸检测试剂盒。公司本次获证的四款产品均采用多重荧光PCR技术，具备高灵敏度、高特异性、操作简便等优势，最快可在30分钟内完成精准鉴别。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","159883","BK1574","09996","09997","BK1100","688289","BK0239","BK1583"],"gpt_icon":0},{"id":"2579498056","title":"藥明巨諾與再生元簽署戰略合作補充協議，攜手加速TCR-T療法開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2579498056","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579498056?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 17:40","pubTimestamp":1761903600,"startTime":"0","endTime":"0","summary":"通过本次补充协议，药明巨诺将获得最高可达5,000万美金的付款，包括MAGE-A4产品开发里程碑付款、药品生产流程监管里程碑付款、选择权行使费、慢病毒载体制造流程里程碑付款。根据补充协议，再生元将为药明巨诺的MAGE-A4靶点产品相关特定开发活动提供资金，于签署修订协议后向本公司支付首付款，并于达成补充协议所载特定开发里程碑事件时支付一系列一次性、不可退还的里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4812260_ZH12260_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","BK1161","BK1574","02126"],"gpt_icon":0}],"pageSize":20,"totalPage":30,"pageCount":1,"totalSize":589,"code":"91000000","status":"200"}]}}